Latay (Latanoprost)

• Latanoprost is a prostaglandin analog used to lower intraocular pressure in glaucoma‑related conditions.
• Open‑angle glaucoma: reduces intraocular pressure to help prevent optic nerve damage and visual field loss.
• Ocular hypertension: lowers intraocular pressure to decrease the risk of developing glaucoma.
• Elevated intraocular pressure: provides sustained pressure reduction to maintain ocular health.

• Latanoprost is a synthetic analogue of prostaglandin F₂α that binds to FP receptors on the ciliary muscle and scleral tissue. Activation of these receptors remodels the extracellular matrix, enhancing uveoscleral outflow of aqueous humor. The increased outflow lowers intraocular pressure, addressing the primary pathogenic factor in open‑angle glaucoma and ocular hypertension. This mechanism operates independently of trabecular meshwork pathways, providing an additive effect when combined with other pressure‑lowering agents.

Latanoprost may cause ocular and peri‑ocular adverse reactions, most of which are mild and transient.

Common Side Effects

• Eye redness (hyperemia)
• Eye irritation or burning sensation
• Increased eyelash growth (hypertrichosis)
• Darkening of the iris (peri‑ocular pigmentation)
• Blurred vision
• Foreign body sensation

Serious or Rare Side Effects

• Uveitis or severe eye inflammation
• Macular edema leading to visual impairment
• Allergic contact dermatitis of the eyelids
• Irregular pupil (anisocoria) with photophobia
• Persistent ocular pain

Before initiating latanoprost therapy, clinicians should consider several safety and handling precautions.

• Monitor intraocular pressure: assess baseline and periodic measurements to evaluate response.
• Assess for ocular infection: avoid use in active conjunctivitis or keratitis.
• Use caution in patients with active ocular inflammation: prostaglandin analogs may exacerbate inflammation.
• Avoid concurrent use with other prostaglandin analog eye drops: risk of additive side effects.
• Evaluate hypersensitivity: discontinue if allergic reaction occurs.
• Store at room temperature: keep bottle tightly closed, protect from light and moisture.

Latanoprost can interact with other ophthalmic or systemic agents, influencing efficacy or safety.

Major Interactions (Avoid)

• Concomitant use with other prostaglandin analogs: may cause excessive intraocular pressure reduction and heightened ocular irritation.
• Use with ocular anesthetic drops containing preservatives: increased risk of corneal toxicity.

Moderate Interactions (Monitor Closely)

• Co‑administration with beta‑blocker eye drops: additive IOP‑lowering effect may lead to hypotony.
• Use with carbonic anhydrase inhibitor eye drops: potential for over‑reduction of intraocular pressure.
• Systemic non‑steroidal anti‑inflammatory drugs: may diminish prostaglandin‑mediated outflow enhancement.
• Topical corticosteroids: may counteract latanoprost’s pressure‑lowering effect.